Promising Radioimmunotherapy Option for Some Lymphomas

July 23, 2013

A phase I/II study found that radioimmunotherapy with 177Lu and the anti-CD20 antibody rituximab along with the chelator DOTA is safe and feasible for treatment of relapsed follicular, mantle cell, or other indolent lymphomas.

“Radioimmunotherapy combines biologic and radiolytic mechanisms to destroy tumor cells,” wrote authors led by Flavio Forrer, MD, PhD, of University Hospital Basel in Switzerland, in a study published in the Journal of Nuclear Medicine. They investigated the use of 177Lu because it has “relatively short tissue penetration range” and may cause less harm to surrounding tissues than other possibilities. The phase I/II study, which included 31 patients, was intended to determine the maximum tolerated dose and to explore clinical response with 177Lu-DOTA-rituximab.